A new five-year study recently concluded in Greece: “The structure-function relationship of oncogenic LMTK3.” The study was conducted by seven institutions in a collaboration effort between three countries in order to determine the structure of LMTK3, which is an important component in the cellular control center. Scientists already know that LMTK3 makes various cancer treatments ineffective. The question is why.
Professor Georgios Giamas os Cancer Cell Signaling at the University of Sussex said, “By solving the crystal structure of LMTK3, we have demonstrated that it possesses all of the hallmarks of an active protein kinase. LMTK3 plays a pivotal role in controlling cellular processes, and we have previously shown that active LMTK3 makes some cancer treatments (eg. chemotherapy and endocrine therapies) less effective.”
Reversing this trend could result in new therapies for various forms of cancer, breast cancer included.
Giamas said, “We are now in the process of taking this research to the next stage by developing LMTK3 specific drugs. We hope that in the next five years we will be undertaking clinical trials, which is incredibly quick for this type of process.”
Also this week, Docwirenews reported a new set of data on the connection between diagnosis timing and socioeconomic status, which is relevant to coronavirus. COVID-19 case rates have resulted in increased wait times between appointments and follow-up appointments. This has resulted in those who have trouble finding money for food and housing to take even longer getting diagnosed with cancer.
Assistant professor of radiology at the Boston University School of Medicine, Michael D. Fishman, M.D., said, “Our findings indicate longer lapses between diagnostic imaging and biopsy for patients with unmet social needs, which begs the question: are unmet social needs associated with some amount of breast cancer mortality that could have been prevented? We seek to investigate this in future work.”